RT Journal Article
SR Electronic
T1 Additional SNPs improve the performance of a polygenic hazard score for prostate cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.11.20188383
DO 10.1101/2020.09.11.20188383
A1 Roshan A. Karunamuni
A1 Minh-Phuong Huynh-Le
A1 Chun C. Fan
A1 Wesley Thompson
A1 Rosalind A. Eeles
A1 Zsofia Kote-Jarai
A1 Kenneth Muir
A1 Artitaya Lophatananon
A1 UKGPCS collaborators
A1 Johanna Schleutker
A1 Nora Pashayan
A1 Jyotsna Batra
A1 APCB BioResource (Australian Prostate Cancer BioResource)
A1 Henrik Grönberg
A1 Eleanor I. Walsh
A1 Emma L. Turner
A1 Athene Lane
A1 Richard M. Martin
A1 David E. Neal
A1 Jenny L. Donovan
A1 Freddie C. Hamdy
A1 Børge G. Nordestgaard
A1 Catherine M. Tangen
A1 Robert J. MacInnis
A1 Alicja Wolk
A1 Demetrius Albanes
A1 Christopher A. Haiman
A1 Ruth C. Travis
A1 Janet L. Stanford
A1 Lorelei A. Mucci
A1 Catharine M. L. West
A1 Sune F. Nielsen
A1 Adam S. Kibel
A1 Fredrik Wiklund
A1 Olivier Cussenot
A1 Sonja I. Berndt
A1 Stella Koutros
A1 Karina Dalsgaard Sørensen
A1 Cezary Cybulski
A1 Eli Marie Grindedal
A1 Jong Y. Park
A1 Sue A. Ingles
A1 Christiane Maier
A1 Robert J. Hamilton
A1 Barry S. Rosenstein
A1 Ana Vega
A1 The IMPACT Study Steering Committee and Collaborators
A1 Manolis Kogevinas
A1 Kathryn L. Penney
A1 Manuel R. Teixeira
A1 Hermann Brenner
A1 Esther M. John
A1 Radka Kaneva
A1 Christopher J. Logothetis
A1 Susan L. Neuhausen
A1 Azad Razack
A1 Lisa F. Newcomb
A1 Canary PASS Investigators
A1 Marija Gamulin
A1 Nawaid Usmani
A1 Frank Claessens
A1 Manuela Gago-Dominguez
A1 Paul A. Townsend
A1 Monique J. Roobol
A1 Wei Zheng
A1 The Profile Study Steering Committee
A1 Ian G. Mills
A1 Ole A. Andreassen
A1 Anders M. Dale
A1 Tyler M. Seibert
A1 The PRACTICAL Consortium
YR 2020
UL http://medrxiv.org/content/early/2020/09/15/2020.09.11.20188383.abstract
AB Background Polygenic hazard scores (PHS) can identify individuals with increased risk of prostate cancer. We estimated the benefit of additional SNPs on performance of a previously validated PHS (PHS46).Materials and Method 180 SNPs, shown to be previously associated with prostate cancer, were used to develop a PHS model in men with European ancestry. A machine-learning approach, LASSO-regularized Cox regression, was used to select SNPs and to estimate their coefficients in the training set (75,596 men). Performance of the resulting model was evaluated in the testing/validation set (6,411 men) with two metrics: (1) hazard ratios (HRs) and (2) positive predictive value (PPV) of prostate-specific antigen (PSA) testing. HRs were estimated between individuals with PHS in the top 5% to those in the middle 40% (HR95/50), top 20% to bottom 20% (HR80/20), and bottom 20% to middle 40% (HR20/50). PPV was calculated for the top 20% (PPV80) and top 5% (PPV95) of PHS as the fraction of individuals with elevated PSA that were diagnosed with clinically significant prostate cancer on biopsy.Results 166 SNPs had non-zero coefficients in the Cox model (PHS166). All HR metrics showed significant improvements for PHS166 compared to PHS46: HR95/50 increased from 3.72 to 5.09, HR80/20 increased from 6.12 to 9.45, and HR20/50 decreased from 0.41 to 0.34. By contrast, no significant differences were observed in PPV of PSA testing for clinically significant prostate cancer.Conclusion Incorporating 120 additional SNPs (PHS166 vs PHS46) significantly improved HRs for prostate cancer, while PPV of PSA testing remained the same.Competing Interest StatementAll authors declare no personal or financial conflicts of interest for the submitted work except as follows. CCF is a scientific consultant for CorTechs Labs, Inc. RE reports honorarium as a speaker for GU-ASCO meeting in San Francisco Jan 2016, support from Janssen, and honorarium as speaker for RMH-FR meeting Nov 2017. She reports honorarium as a speaker at the University of Chicago invited talk May 2018, and an educational honorarium by Bayer & Ipsen to attend GU Connect Treatment sequencing for mCRPC patients within the changing landscape of mHSPC at ESMO Barcelona, Sep 2019. She reports member of external Expert Committee on the Prostate Dx Advisory Panel. OAA received speaker honorarium from Lundbeck, and is a consultant for Healthlytix. AMD reports that he was a founder and holds equity in CorTechs Labs Inc., and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc., and the Mohn Medical Imaging and Visualization Centre. He received funding through research grants from GE Healthcare to UCSD. The terms of these arrangements have been reviewed by and approved by UCSD in accordance with its conflict of interest policies. TMS reports honoraria, outside of the present work, from: University of Rochester, Varian Medical Systems, Multimodal Imaging Servcies Corporation; and WebMD. He reports research funding from NIH/NBIB, U.S. Department of Defense, Radiological Society of North America, American Society for Radiation Oncology, and Varian Medical Systems.Funding StatementThis study was funded in part by a grant from the United States National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (#K08EB026503), the Research Council of Norway (#223273), KG Jebsen Stiftelsen, and South East Norway Health Authority.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All contributing studies were approved by the relevant ethics committees and performed in accordance with the Declaration of Helsinki; written informed consent was obtained from the study participants. The present analyses used de-identified data from the PRACTICAL consortium and have been approved by the review board at the corresponding authors institution.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this work were obtained from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) consortium. Readers who are interested in accessing the data must first submit a proposal to the Data Access Committee. If the reader is not a member of the consortium, their concept form must be sponsored by a principal investigator (PI) of one of the PRACTICAL consortium member studies. If approved by the Data Access Committee, PIs within the consortium, each of whom retains ownership of their data submitted to the consortium, can then choose to participate in the specific proposal. In addition, portions of the data are available for request from dbGaP (database of Genotypes and Phenotypes) which is maintained by the National Center for Biotechnology Information (NCBI): https://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostatehttps://www.ncbi.nlm.nih.gov/gap/?term=Icogs+prostate. Anyone can apply to join the consortium. The eligibility requirements are listed here: http://practical.icr.ac.uk/blog/?page_id=9. Joining the consortium would not guarantee access, as a proposal for access would still be submitted to the Data Access Committee, but there would be no need for a separate member sponsor. Readers may find information about application by using the contact information below: Rosalind Eeles Principal Investigator for PRACTICAL Professor of Oncogenetics Institute of Cancer Research (ICR) Sutton, UK Email: PRACTICAL@icr.ac.uk URL: http://practical.icr.ac.uk Tel: ++44 (0)20 8722 4094